Showing results (1781-1790 of 1,865) with videos related to
Sort By:
Pageof 187
Science (New York, N.Y.)|May 21, 2026
In Science JournalsJesse Smith, Corinne Simonti, Keith T Smith, et al.ACS Chemical Neuroscience|August 9, 2016
Aryl Sulfonamide Inhibitors of Insulin-Regulated Aminopeptidase Enhance Spine Density in Primary Hippocampal Neuron CulturesShanti Diwakarla, Erik Nylander, Alfhild Grönbladh, et al.JAMA Pediatrics|February 1, 2021
Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical TrialAnn Hellström, Anders K Nilsson, Dirk Wackernagel, et al.Public Health Nutrition|July 10, 2007
Assessing, understanding and modifying nutritional status, eating habits and physical activity in European adolescents: the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) StudyL A Moreno, M González-Gross, M Kersting, et al.Science (New York, N.Y.)|June 27, 2024
In Science JournalsL Bryan Ray, Brent Grocholski, Michael A Funk, et al.Circulation|November 26, 2008
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?Elena Kaschina, Aleksandra Grzesiak, Jun Li, et al.The EMBO Journal|January 7, 2021
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationMarcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, et al.Cell Reports|September 23, 2020
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in NeuroblastomaJoachim Tetteh Siaw, Niloufar Javanmardi, Jimmy Van den Eynden, et al.Scientific Reports|January 16, 2020
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressivenessLiselot M Mus, Irina Lambertz, Shana Claeys, et al.Cold Spring Harbor Molecular Case Studies|June 17, 2018
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibJikui Guan, Susanne Fransson, Joachim Tetteh Siaw, et al.Pageof 187